Heart Rate Deceleration Emerges as a Readout of Antidepressant Response in Accelerated dmPFC iTBS
A low-cost chest-strap monitor captured a physiologic signal that moved in step with antidepressant benefit during accelerated intermittent theta-burst stimulation of the dorsomedial prefrontal cortex in major depressive disorder. In this cohort of 32 patients, stimulation-evoked heart rate deceleration separated responders from non-responders with an effect size large enough to draw immediate attention from anyone trying to make transcranial magnetic stimulation more measurable at the bedside. Response was defined as at least a 50% reduction in 17-item Hamilton Depression Rating Scale score, and remission was defined by the study’s clinical criteria; the response rate reached 65.6%, while remission reached 56.3%.
The signal itself is simple. Heart rate was sampled every second, then compared with a one-minute prestimulation baseline across the stimulation window. Patients who ultimately responded showed a larger slowing of heart rate during stimulation than those who did not, with a Cohen’s d of 1.40. For a biomarker concept built around real-time physiology rather than costly imaging or lab work, that magnitude matters because it suggests the autonomic nervous system is not just a passive bystander during cortical stimulation. It may be participating in the therapeutic effect.
One sentence captures the practical appeal: a chest strap may do what a scanner cannot do at the point of treatment.
A Prefrontal-Autonomic Signal That Tracks Clinical Benefit
Accelerated bilateral dmPFC-iTBS was delivered with a double-cone coil, targeting a cortical region tied to executive control, emotion regulation, and autonomic integration. That neuroanatomy makes the heart rate finding biologically plausible. The dorsomedial prefrontal cortex has dense connections with networks that influence sympathetic and parasympathetic output, so a slowing pulse during stimulation can reasonably be read as a marker of network engagement rather than a random epiphenomenon. In depression research, this matters because many patients improve slowly, unevenly, or not at all, and clinicians have long lacked a cheap way to tell whether a stimulation protocol is reaching the right circuit early enough to inform treatment decisions.
Discrimination of responders was strong. The area under the curve reached 0.905, and a 2% cutoff produced 90.5% sensitivity and 81.8% specificity. Each 1% increase in heart rate deceleration was associated with roughly 2.5-fold higher odds of response. Those are not subtle shifts. They suggest that the autonomic response to stimulation may be carrying actionable information before a full antidepressant trial has played out, potentially opening the door to session-by-session optimization. In a field where clinicians often wait weeks to know whether a protocol is worth continuing, a physiologic signal recorded during treatment could compress that feedback loop.
The study also positions this biomarker as accessible rather than exotic. Continuous heart rate sampling with a chest strap is inexpensive, portable, and easy to standardize compared with advanced neuroimaging or specialized electrophysiology. If the finding survives larger validation, it would fit well in outpatient settings where speed, simplicity, and scalability shape what actually gets used.
Why the Finding Is Intriguing, and Why It Still Needs Sharper Proof
The association between stimulation-evoked heart rate slowing and antidepressant response fits a broader model of depression as a disorder involving both cortical and autonomic dysregulation. If dmPFC stimulation nudges a prefrontal-autonomic network toward a more regulated state, heart rate deceleration could reflect that immediate physiologic shift. The interpretation is attractive because it links a bedside measurement to a mechanistic hypothesis rather than treating the biomarker as a black box. It also aligns with a growing literature examining cardiac autonomic control in depression and brain-heart coupling during treatment.
Still, the study leaves important questions open. The sample was small, and the design lacked a sham-controlled comparator in the report presented here, so the strength of causal inference remains limited. A retrospective trial registration also narrows how confidently the field can view the biomarker analysis as prospectively specified. Those constraints do not erase the signal, but they do define the level of caution needed before anyone treats heart rate deceleration as a validated decision tool.
The study’s own structure also points to the next step. Larger sham-controlled cohorts will need to confirm whether the effect persists across sites, stimulation protocols, and patient subgroups, and whether the cutoff remains stable when measured under routine clinical conditions rather than in a research environment. If the autonomic signal holds, it could become a practical companion marker for accelerated TMS, helping clinicians identify early who is likely to benefit from continued dmPFC stimulation and who may need a different strategy.
For now, the central result is concrete: a brief physiologic slowing of the pulse during stimulation tracked antidepressant response with impressive accuracy in a small cohort of patients with major depression. The finding is promising because it is measurable, inexpensive, and mechanistically coherent. It is also provisional, and its clinical value will depend on whether the same pattern appears when the experiment is repeated at larger scale under stricter prospective control.